Reply

In his letter, Dr Ophir re-emphasizes the modest gains received by many patients from intensive treatment and monitoring with ranibizumab plus prompt focal/grid laser treatment in the Protocol I study.2,3 In response to our statement that an effective treatment algorithm for DME is uncertain in this...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of ophthalmology Vol. 177; p. 231
Main Authors Gonzalez, Victor H, Campbell, Joanna, Holekamp, Nancy M, Kiss, Szilárd, Loewenstein, Anat, Augustin, Albert J, Ma, Julia, Ho, Allen C, Patel, Vaishali, Whitcup, Scott M, Dugel, Pravin U
Format Journal Article
LanguageEnglish
Published Chicago Elsevier Limited 01.05.2017
Subjects
Authorship
Clinical trials
Diabetes
Diabetic retinopathy
Edema
Lasers
Medical diagnosis
Monoclonal antibodies
Ophthalmology
Pharmaceutical industry
Vascular endothelial growth factor
United States > US
California
Online AccessGet full text

Cover

More Information
Summary:In his letter, Dr Ophir re-emphasizes the modest gains received by many patients from intensive treatment and monitoring with ranibizumab plus prompt focal/grid laser treatment in the Protocol I study.2,3 In response to our statement that an effective treatment algorithm for DME is uncertain in this group of suboptimal responders, he offers a systematic evidence-based approach to diagnosis and treatment of diffuse diabetic macular edema (DDME) that relies on the choice of full-field 3D optical...
ISSN:0002-9394
1879-1891
DOI:10.1016/j.ajo.2017.02.009